---
title: "BUZZ-Uptake of Dexcom's OTC glucose monitor Stelo outpaces Abbott's Lingo, Citi says"
description: "Citi reports that Dexcom's over-the-counter glucose monitor, Stelo, is outperforming Abbott's Lingo in early uptake. Stelo's earlier launch has contributed to its success. Additionally, app downloads "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/215729267.md"
published_at: "2024-10-01T15:53:38.000Z"
---

# BUZZ-Uptake of Dexcom's OTC glucose monitor Stelo outpaces Abbott's Lingo, Citi says

> Citi reports that Dexcom's over-the-counter glucose monitor, Stelo, is outperforming Abbott's Lingo in early uptake. Stelo's earlier launch has contributed to its success. Additionally, app downloads for Dexcom's G7 monitor reached record highs in August, following a slow start earlier in the year. In contrast, Abbott's FreeStyle Libre 3 faced challenges with app downloads in May and June. Year-to-date, Dexcom shares have dropped approximately 47%, while Abbott's shares have increased by about 3%.

Brokerage Citi says early uptake of Dexcom’s (DXCM.O) over-the-counter continuous glucose monitor Stelo is ahead of Abbott’s (ABT.N) Lingo

Stelo is gaining traction benefitting from an earlier launch compared to Lingo - Citi

Adds app data points to a recovery for Dexcom, after the glucose monitor maker slashed its annual revenue forecast

Brokerage says downloads of apps for Dexcom’s continuous glucose monitor G7 went up in August, setting a record high in downloads since launch, after a slower April, May and June with a slight uptick in July

Adds U.S. downloads of apps for ABT’s FreeStyle Libre 3 seem to have struggled in May and June, with a stable July, followed by a more difficult August

DXCM shares have fallen ~47%, while ABT up ~3% YTD

### Related Stocks

- [DXCM.US - DexCom](https://longbridge.com/en/quote/DXCM.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Eagle Health Investments LP Decreases Stock Position in DexCom, Inc. $DXCM | Eagle Health Investments LP reduced its stake in DexCom, Inc. by 23.3% in Q2, selling 83,100 shares. DexCom's stock open | [Link](https://longbridge.com/en/news/266887675.md) |
| DexCom Faces Class Action Lawsuit Over Alleged Securities Fraud | DexCom Inc. is facing a class action lawsuit for alleged securities fraud, affecting investors between January 8, 2024,  | [Link](https://longbridge.com/en/news/269141004.md) |
| Dexcom Executive Jacob Steven Leach Acquires 18,200 Shares | Jacob Steven Leach, President & COO of Dexcom and a 10% owner, acquired 18,200 shares of common stock on November 10, 20 | [Link](https://longbridge.com/en/news/265236283.md) |
| Class Action Litigation Filed by Pomerantz LLP for Investors of DexCom, Inc. – DXCM | Pomerantz LLP has filed a class action lawsuit against DexCom, Inc. and certain officers, alleging violations of federal | [Link](https://longbridge.com/en/news/269146697.md) |
| Class Action Litigation Now Underway by Pomerantz LLP Against DexCom, Inc. – DXCM | Pomerantz LLP has filed a class action lawsuit against DexCom, Inc. and certain officers, alleging violations of federal | [Link](https://longbridge.com/en/news/269296227.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.